251 related articles for article (PubMed ID: 36388243)
1. Corneal Refractive Surgery Considerations in Patients with Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders.
Moshirfar M; Brown AH; Sulit CA; Corbin WM; Ronquillo YC; Hoopes PC
Int Med Case Rep J; 2022; 15():647-656. PubMed ID: 36388243
[TBL] [Abstract][Full Text] [Related]
2. Acute Recurrent and Chronic Pancreatitis as Initial Manifestations of Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders.
Baldwin C; Zerofsky M; Sathe M; Troendle DM; Perito ER
Pancreas; 2019 Aug; 48(7):888-893. PubMed ID: 31268981
[TBL] [Abstract][Full Text] [Related]
3. Ocular Changes in Cystic Fibrosis: A Review.
Liberski S; Confalonieri F; Cofta S; Petrovski G; Kocięcki J
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928397
[TBL] [Abstract][Full Text] [Related]
4. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis.
Karb DB; Cummings LC
Curr Gastroenterol Rep; 2021 Aug; 23(10):17. PubMed ID: 34448955
[TBL] [Abstract][Full Text] [Related]
5. Genetic diagnosis in practice: From cystic fibrosis to CFTR-related disorders.
Pagin A; Sermet-Gaudelus I; Burgel PR
Arch Pediatr; 2020 Feb; 27 Suppl 1():eS25-eS29. PubMed ID: 32172933
[TBL] [Abstract][Full Text] [Related]
6. CFTR dysfunction in cystic fibrosis and chronic obstructive pulmonary disease.
Fernandez Fernandez E; De Santi C; De Rose V; Greene CM
Expert Rev Respir Med; 2018 Jun; 12(6):483-492. PubMed ID: 29750581
[TBL] [Abstract][Full Text] [Related]
7. Non-pulmonary CFTR-related symptom improvement with ivacaftor in p.Phe508del/p.Arg117His (7T) cystic fibrosis.
Kuek SL; Massie RJH
Respirol Case Rep; 2023 Jan; 11(1):e01079. PubMed ID: 36569635
[TBL] [Abstract][Full Text] [Related]
8. Variability of Clinical Presentation in Patients Heterozygous for the F508del Cystic Fibrosis Variant: A Series of Three Cases and a Review of the Literature.
Raymond CM; Gaul SP; Han S; Huang G; Dong J
Cureus; 2023 Jun; 15(6):e40185. PubMed ID: 37431359
[TBL] [Abstract][Full Text] [Related]
9. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis.
Ooi CY; Durie PR
J Cyst Fibros; 2012 Sep; 11(5):355-62. PubMed ID: 22658665
[TBL] [Abstract][Full Text] [Related]
10. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease.
Gonska T; Choi P; Stephenson A; Ellis L; Martin S; Solomon M; Dupuis A; Dorfman R; Zielenski J; Ooi CY; Weiser W; Durie PR; Tullis E
Chest; 2012 Oct; 142(4):996-1004. PubMed ID: 22423042
[TBL] [Abstract][Full Text] [Related]
11. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
12. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
Bienvenu T; Sermet-Gaudelus I; Burgel PR; Hubert D; Crestani B; Bassinet L; Dusser D; Fajac I
Am J Respir Crit Care Med; 2010 May; 181(10):1078-84. PubMed ID: 20167849
[TBL] [Abstract][Full Text] [Related]
13. CFTR genotype and clinical outcomes of adult patients carried as cystic fibrosis disease.
Bonadia LC; de Lima Marson FA; Ribeiro JD; Paschoal IA; Pereira MC; Ribeiro AF; Bertuzzo CS
Gene; 2014 May; 540(2):183-90. PubMed ID: 24583165
[TBL] [Abstract][Full Text] [Related]
14. State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (
Meoli A; Fainardi V; Deolmi M; Chiopris G; Marinelli F; Caminiti C; Esposito S; Pisi G
Pharmaceuticals (Basel); 2021 Sep; 14(9):. PubMed ID: 34577628
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of Cystic Fibrosis in Nonscreened Populations.
Sosnay PR; White TB; Farrell PM; Ren CL; Derichs N; Howenstine MS; Nick JA; De Boeck K
J Pediatr; 2017 Feb; 181S():S52-S57.e2. PubMed ID: 28129813
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis transmembrane conductance regulator function, not TAS2R38 gene haplotypes, predict sinus surgery in children and young adults with cystic fibrosis.
Dalesio NM; Aksit MA; Ahn K; Raraigh KS; Collaco JM; McGrath-Morrow S; Zeitlin PL; An SS; Cutting GR
Int Forum Allergy Rhinol; 2020 Jun; 10(6):748-754. PubMed ID: 32282124
[TBL] [Abstract][Full Text] [Related]
17. Cystic-fibrosis-like disease unrelated to the cystic fibrosis transmembrane conductance regulator.
Mekus F; Ballmann M; Bronsveld I; Dörk T; Bijman J; Tümmler B; Veeze HJ
Hum Genet; 1998 May; 102(5):582-6. PubMed ID: 9654209
[TBL] [Abstract][Full Text] [Related]
18. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
[TBL] [Abstract][Full Text] [Related]
19. Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients.
Schippa S; Iebba V; Santangelo F; Gagliardi A; De Biase RV; Stamato A; Bertasi S; Lucarelli M; Conte MP; Quattrucci S
PLoS One; 2013; 8(4):e61176. PubMed ID: 23613805
[TBL] [Abstract][Full Text] [Related]
20. Changing paradigms in the treatment of gastrointestinal complications of cystic fibrosis in the era of cystic fibrosis transmembrane conductance regulator modulators.
Konrad J; Eber E; Stadlbauer V
Paediatr Respir Rev; 2022 Jun; 42():9-16. PubMed ID: 33485777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
